Brain volume abnormalities and neurocognitive deficits in diabetes mellitus: Points of pathophysiological commonality with mood disorders?

Mood Disorders/Psychopharmacology Unit, University Health Network, University of Toronto, 399 Bathurst Street, Toronto, Ontario, Canada.
Advances in Therapy (Impact Factor: 2.27). 04/2010; 27(2):63-80. DOI: 10.1007/s12325-010-0011-z
Source: PubMed


It is hypothesized that diabetes mellitus (DM) and mood disorders share points of pathophysiological commonality in the central nervous system.
A PubMed search of all English-language articles published between 1966 and March 2009 was performed with the following search terms: depression, mood disorders, hippocampus, amygdala, central nervous system, brain, neuroimaging, volumetric, morphometric, and neurocognitive deficits, cross-referenced with DM. Articles selected for review were based on adequacy of sample size, the use of standardized experimental procedures, validated assessment measures, and overall manuscript quality. The primary author was principally responsible for adjudicating the merit of articles that were included.
Volumetric studies indicate that individuals with Type 1/2 DM exhibit regional abnormalities in both cortical and subcortical (e.g., hippocampus, amygdala) brain structures. The pattern of neurocognitive deficits documented in individuals with Type 1 DM overlap with Type 2 populations, with suggestions of discrete abnormalities unique to each phenotype. The pattern of volumetric and neurocognitive deficits in diabetic populations are highly similar to that reported in populations of individuals with major depressive disorder.
The prevailing models of disease pathophysiology in DM and major depressive disorder are distinct. Notwithstanding, the common abnormalities observed in disparate effector systems (e.g., insulin resistance, immunoinflammatory activation) as well as brain volume and neurocognitive performance provide the nexus for hypothesizing that both conditions are subserved by overlapping pathophysiology. This conception provides a novel framework for disease modeling and treatment development in mood disorder.

Download full-text


Available from: Sidney H Kennedy,
  • Source
    • "Our mediation findings extend prior findings linking peripheral physiological changes associated with the MetS and depressive symptomatology by identifying a potential mediating factor: reduced globus pallidus volume. As noted previously, this observation is consistent with prior findings and speculations that the MetS and depressive symptoms may share common pathophysiological features [22], including alterations in central neurotransmitter systems that covary with metabolic dysregulation [58] [59] and risk for depressive symptoms [81], as well as volume reductions in basal ganglia regions [74] [82]. Again, however, the causal directions of associations and temporal ordering of depressive symptoms, volumetric changes, and depressive symptoms need to be tested in future longitudinal research. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The metabolic syndrome (MetS) is a clustering of cardiovascular and cerebrovascular risk factors that are often comorbid with depressive symptoms. Individual components of the MetS also covary with the morphology of basal ganglia regions that are altered by depression. However, it remains unknown whether the covariation between the MetS and depressive symptomatology can be accounted for in part by morphological changes in the basal ganglia. Accordingly, we tested the hypothesis that increased depressive symptoms among individuals with the MetS might be statistically mediated by reduced grey matter volume in basal ganglia regions. The presence of the MetS was determined in 147 middle-aged adults using the criteria of the National Cholesterol Education Program, Adult Treatment Panel III. Basal ganglia volumes were determined on an a priori basis by automated segmentation of high-resolution magnetic resonance images. Depressive symptoms were assessed using the Patient Health Questionnaire. Even after controlling for demographic and other confounding factors, having the MetS and meeting more MetS criteria covaried with reduced globus pallidus volume. Meeting more MetS criteria and reduced pallidal volume were also related to depressive symptoms. Moreover, the MetS-depression association was statistically mediated by pallidal volume. In summary, reduced globus pallidus volume is a neural correlate of the MetS that may partly account for its association with depressive symptoms.
    Physiology & Behavior 10/2013; 123. DOI:10.1016/j.physbeh.2013.09.014 · 2.98 Impact Factor
  • Source
    • "Diabetes may place patients at risk for depression through a biological mechanism linking the metabolic changes of DM to changes in the CNS.9 Keeping with this perspective, McIntyre et al10 demonstrated that a common point of pathophysiology exists between MDD and DM when considering brain volume abnormalities and neurocognitive deficits. In this review, we discuss the literature pertinent to EEG abnormalities in DM, but we also discuss biological mechanisms underlying each EEG parameter discussed, in order to evaluate whether or not a common link exists between neurobiological mechanisms associated with EEG findings in DM and in MDD. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A bidirectional relationship exists between diabetes mellitus (DM) and major depressive disorder (MDD), with depression commonly reported in both type 1 DM (T1DM) and type 2 DM (T2DM), and depressive symptoms associated with a higher incidence of diabetes. However, how the two conditions are pathologically connected is not completely understood. Similar neurophysiological abnormalities have been reported in both DM and MDD, including elevated electroencephalographic (EEG) activity in low-frequency slow waves and increased latency and/or reduced amplitude of event-related potentials. It is possible that this association reflects some common underlying pathology, and it has been proposed that diabetes may place patients at risk for depression through a biological mechanism linking the metabolic changes of DM to changes in the central nervous system. In this review we will discuss EEG abnormalities in DM, as well as the biological mechanisms underlying various EEG parameters, in order to evaluate whether or not a common EEG biosignature exists between DM and MDD. Identifying such commonalities could significantly inform the current understanding of the mechanisms that subserve the development of the two conditions. Moreover, this new insight may provide the basis for informing new drug discovery capable of mitigating and possibly even preventing both conditions.
    Neuropsychiatric Disease and Treatment 01/2013; 9(1):143-50. DOI:10.2147/NDT.S38720 · 1.74 Impact Factor
  • Source
    • "Severe hypoglycemia leads to uncontrolled release of excitatory amino acids, such as glutamate and aspartate, triggering a cascade of events that may result in neuronal damage (1), whereas chronically elevated glucose levels induce a form of glucose neurotoxicity (2). Variations in insulin and counterregulatory hormone levels may also be neurotoxic (3,4). "
    [Show abstract] [Hide abstract]
    ABSTRACT: 2 Childhood-onset type 1 diabetes is associated with neurocognitive deficits, but there is limited evidence to date regarding associated neuroanatomical brain changes and their relationship to illness variables such as age at disease onset. This report examines age-related changes in volume and T2 relaxation time (a fundamental parameter of magnetic resonance imaging that reflects tissue health) across the whole brain. Type 1 diabetes, N = 79 (mean age 20.32 ± 4.24 years), and healthy control participants, N = 50 (mean age 20.53 ± 3.60 years). There were no substantial group differences on socioeconomic status, sex ratio, or intelligence quotient. Regression analyses revealed a negative correlation between age and brain changes, with decreasing gray matter volume and T2 relaxation time with age in multiple brain regions in the type 1 diabetes group. In comparison, the age-related decline in the control group was small. Examination of the interaction of group and age confirmed a group difference (type 1 diabetes vs. control) in the relationship between age and brain volume/T2 relaxation time. We demonstrated an interaction between age and group in predicting brain volumes and T2 relaxation time such that there was a decline in these outcomes in type 1 diabetic participants that was much less evident in control subjects. Findings suggest the neurodevelopmental pathways of youth with type 1 diabetes have diverged from those of their healthy peers by late adolescence and early adulthood but the explanation for this phenomenon remains to be clarified.
    Diabetes care 03/2012; 35(3):513-9. DOI:10.2337/dc11-1290 · 8.42 Impact Factor
Show more